Literature DB >> 8994315

In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid.

R K Gupta1, A C Chang, P Griffin, R Rivera, G R Siber.   

Abstract

Radiolabeled tetanus toxoid (TT) was prepared by detoxifying chromatographically purified tetanus toxin with 14C-labeled formaldehyde. 14C-TT was encapsulated inside poly (D,L-lactide-co-glycolide, 50/50) microspheres (MS) of varying average size (approximately 10 microns and approximately 50 microns). Balb/c mice were injected subcutaneously with 5 Lf (approximately 15 micrograms) of 14C-TT, encapsulated in MS, mixed with blank MS without encapsulated antigen, as soluble antigen or adsorbed onto aluminum phosphate (AlPO4) and radioactivity was monitored at the site of injection, draining lymph nodes, blood, liver, spleen, and kidneys at various intervals. At one day, approximately 95% and 90% radioactivity disappeared from site of injection for soluble TT or blank MS mixed TT and AlPO4 adsorbed TT, respectively, whereas approximately 55% and 70% radioactivity disappeared from site of injection for MS of average size approximately 50 microns and approximately 10 microns, respectively. By 7 days, 99% of radioactivity disappeared from site of injection for soluble TT or blank MS mixed TT, whereas 2-3% radioactivity persisted at the site of injection for AlPO4 adsorbed TT for 4 weeks. In contrast, approximately 20% radioactivity stayed at the site of injection for MS injected mice up to 4 weeks. At all time points, large MS (approximately 50 microns) showed more radioactivity at the site of injection than small MS (approximately 10 microns). Other organs showing radioactivity were draining lymph nodes and kidneys. Small MS with encapsulated TT showed highest level of radioactivity in lymph nodes at 4 h. In kidneys, soluble and AlPO4 adsorbed TT showed a peak of radioactivity at 4 h whereas TT encapsulated in MS showed a peak of radioactivity at 7 days. These results indicate that AlPO4 did not act as a depot for TT at the site of injection, but TT encapsulated in MS did form a depot for approximately 1 month.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8994315     DOI: 10.1016/s0264-410x(96)00073-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

2.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

3.  Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.

Authors:  Yue Zhang; Min Li; Fan Yang; Yufang Li; Zizheng Zheng; Xiao Zhang; Qingshan Lin; Ying Wang; Shaowei Li; Ningshao Xia; Jun Zhang; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 4.  Beyond antigens and adjuvants: formulating future vaccines.

Authors:  Tyson J Moyer; Andrew C Zmolek; Darrell J Irvine
Journal:  J Clin Invest       Date:  2016-03-01       Impact factor: 14.808

Review 5.  Engineering synthetic vaccines using cues from natural immunity.

Authors:  Darrell J Irvine; Melody A Swartz; Gregory L Szeto
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

Review 6.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Developing a vaccine against multiple psychoactive targets: a case study of heroin.

Authors:  G Neilm Stowe; Joel E Schlosburg; Leandro F Vendruscolo; Scott Edwards; Kaushik K Misra; Gery Schulteis; Joseph S Zakhari; George F Koob; Kim D Janda
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-12       Impact factor: 4.388

8.  In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles.

Authors:  Christopher M Jewell; Sandra C Bustamante López; Darrell J Irvine
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-06       Impact factor: 11.205

9.  Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats.

Authors:  Hyun-Hee Kwak; Won-Sik Shim; Seongmee Hwang; Mi-Kyung Son; Yoon-Ji Kim; Tae-Hyoung Kim; Zee-Hye Yoon; Hyun-Jun Youn; Ghun-Il Lee; Soo-Hyoung Kang; Chang-Koo Shim
Journal:  Pharm Res       Date:  2009-09-11       Impact factor: 4.200

10.  Interleukin-4- and NACHT, LRR and PYD domains-containing protein 3-independent mechanisms of alum enhanced T helper type 2 responses on basophils.

Authors:  Feng-Juan Huang; Yi-Lei Ma; Ruo-Yu Tang; Wen-Ci Gong; Jun Li; Chun-Xia Chen; Lan Yin; Xiao-Ping Chen
Journal:  Immunology       Date:  2016-08-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.